ID

34479

Beschrijving

Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01784757

Link

https://clinicaltrials.gov/show/NCT01784757

Trefwoorden

  1. 17-01-19 17-01-19 -
  2. 22-05-19 22-05-19 -
Houder van rechten

GSK group of companies

Geüploaded op

17 januari 2019

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY-NC 3.0

Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Prostate Cancer NCT01784757

Eligibility Prostate Cancer NCT01784757

Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
written informed consent (ic) obtained.
Beschrijving

ID.1

Datatype

boolean

histologically confirmed adenocarcinoma of prostate
Beschrijving

ID.2

Datatype

boolean

progressive metastatic disease
Beschrijving

ID.3

Datatype

boolean

ongoing androgen deprivation therapy with a luteinising hormone-releasing hormone (lhrh) analogue or antagonist or bilateral orchiectomy
Beschrijving

ID.4

Datatype

boolean

adequate bone marrow, hepatic and renal function
Beschrijving

ID.5

Datatype

boolean

able to swallow the odm-201 whole as a capsule or tablet.
Beschrijving

ID.6

Datatype

boolean

Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
previous chemotherapy for prostate cancer.
Beschrijving

ID.7

Datatype

boolean

known metastases in the brain.
Beschrijving

ID.8

Datatype

boolean

history of other malignancy within the previous 5 years, except a basal cell carcinoma of skin.
Beschrijving

ID.9

Datatype

boolean

known gastrointestinal condition that can significantly affect the absorption of the study treatment.
Beschrijving

ID.10

Datatype

boolean

Similar models

Eligibility Prostate Cancer NCT01784757

Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
written informed consent (ic) obtained.
boolean
ID.2
Item
histologically confirmed adenocarcinoma of prostate
boolean
ID.3
Item
progressive metastatic disease
boolean
ID.4
Item
ongoing androgen deprivation therapy with a luteinising hormone-releasing hormone (lhrh) analogue or antagonist or bilateral orchiectomy
boolean
ID.5
Item
adequate bone marrow, hepatic and renal function
boolean
ID.6
Item
able to swallow the odm-201 whole as a capsule or tablet.
boolean
Item Group
C0680251 (UMLS CUI)
ID.7
Item
previous chemotherapy for prostate cancer.
boolean
ID.8
Item
known metastases in the brain.
boolean
ID.9
Item
history of other malignancy within the previous 5 years, except a basal cell carcinoma of skin.
boolean
ID.10
Item
known gastrointestinal condition that can significantly affect the absorption of the study treatment.
boolean

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial